COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysisJuan Ignacio Ruiz, Maria Angeles Lopez-Olivo, Yimin Geng, Maria E Suarez-Almazor
6 February 2023
SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry reportKevin Owen McNerney, Rebecca M Richards, Paibel Aguayo-Hiraldo, Friso G Calkoen, Julie-An Talano, Amy Moskop, Adriana Balduzzi, Jennifer Krajewski, Hema Dave, Anant Vatsayan, Colleen Callahan, Hongyan Liu, Yimei Li, Kara Lynn Davis, Shannon L Maude
27 January 2023
Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapySimon Deycmar, Bruno Gomes, Jehad Charo, Maurizio Ceppi, J Mark Cline
2 January 2023
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registriesAlessio Cortellini, Gino M Dettorre, Urania Dafni, Juan Aguilar-Company, Luis Castelo-Branco, Matteo Lambertini, Spyridon Gennatas, Vasileios Angelis, Ailsa Sita-Lumsden, Jacobo Rogado, Paolo Pedrazzoli, David Viñal, Aleix Prat, Maura Rossi, Rossana BerardiSee the full list of authors
30 November 2022
T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccineDjordje Atanackovic, Robert J Kreitman, Jeffrey Cohen, Nancy M Hardy, Destiny Omili, Thierry Iraguha, Peter D Burbelo, Etse Gebru, Xiaoxuan Fan, John Baddley, Tim Luetkens, Saurabh Dahiya, Aaron P Rapoport
17 July 2022
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapiesSherin Juliet Rouhani, Jovian Yu, Daniel Olson, Yuanyuan Zha, Apameh Pezeshk, Alexandra Cabanov, Athalia R Pyzer, Jonathan Trujillo, Benjamin A Derman, Peter O'Donnell, Andrzej Jakubowiak, Hedy L Kindler, Christine Bestvina, Thomas F Gajewski
22 June 2022
JAK inhibitors and COVID-19Gabriel Levy, Paola Guglielmelli, Peter Langmuir, Stefan N Constantinescu
22 April 2022
Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world studyQi Mei, Guangyuan Hu, Yang Yang, Bo Liu, Junping Yin, Ming Li, Qiao Huang, Xi Tang, Alexander Böhner, Amy Bryant, Christian Kurts, Xianglin Yuan, Jian Li
9 March 2022
Spontaneous tumor regression following COVID-19 vaccinationLuana Guimaraes de Sousa, Daniel J McGrail, Kaiyi Li, Mario L Marques-Piubelli, Cipriano Gonzalez, Hui Dai, Sammy Ferri-Borgogno, Myrna Godoy, Jared Burks, Shiaw-Yih Lin, Diana Bell, Renata Ferrarotto
3 March 2022
Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysisYifei Ma, Nianqi Liu, Youlong Wang, Jiling Zeng, Ying-Ying Hu, Wu Hao, Huazheng Shi, Pengfei Zhu, Jun Lv, Wei Fan, Xinjia Wang
29 November 2021